Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Trifluoperazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 3/20 | 0.98 |
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 0.98 |
| ▸ | HTR2C known ✓ | P28335 | 3/20 | 0.98 |
| ▸ | DRD3 known ✓ | P35462 | 3/20 | 0.98 |
| ▸ | DRD4 known ✓ | P21917 | 2/20 | 0.80 |
| ▸ | LMNA | P02545 | 7/20 | 1.00 |
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 5/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 1.00 |
| ▸ | TP53 | P04637 | 4/20 | 1.00 |
| ▸ | USP2 | O75604 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | GMNN | O75496 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoperazine SCHEMBL341516 | 1.00 | LMNA (1.00) | LMNAMAPTSMN1; SMN2CYP3A4MAPK1 | |
| Trifluoperazine SCHEMBL23039392 | 1.00 | LMNA (1.00) | LMNAMAPTSMN1; SMN2CYP3A4MAPK1 | |
| Trifluoperazine SCHEMBL29579627 | 1.00 | LMNA (1.00) | LMNAMAPTSMN1; SMN2CYP3A4MAPK1 | |
| Trifluoperazine SCHEMBL29430171 | 1.00 | LMNA (1.00) | LMNAMAPTSMN1; SMN2CYP3A4MAPK1 | |
| Trifluoperazine SCHEMBL1897003 | 0.99 | FPR2 (1.00) | LMNAMAPTSMN1; SMN2CYP3A4MAPK1 | |
| Trifluoperazine SCHEMBL29603012 | 0.99 | FPR2 (1.00) | LMNAMAPTSMN1; SMN2CYP3A4MAPK1 | |
| Trifluoperazine SCHEMBL24866 | 0.99 | FPR2 (1.00) | LMNAMAPTSMN1; SMN2CYP3A4MAPK1 | |
| Trifluoperazine SCHEMBL466955 | 0.97 | FPR2 (0.96) | LMNAMAPTSMN1; SMN2CYP3A4MAPK1 | |
| SCHEMBL21445272 | 0.97 | FPR2 (1.00) | LMNAMAPTSMN1; SMN2CYP3A4MAPK1 | |
| Trifluoperazine SCHEMBL28329317 | 0.94 | FPR2 (0.90) | LMNAMAPTSMN1; SMN2CYP3A4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3731 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119662803-A | Application of synaptotagmin 11 as marker in preparation of products for diagnosis, auxiliary diagnosis, screening or auxiliary screening of schizophrenia | 深圳百脉得生物科技有限公司 | 2025-03-21 | — | — | CN | claimed |
| EP-2796112-B2 | Degradable implantable medical devices | ELIXIR MEDICAL CORP (US) | 2023-08-09 | — | — | EP | claimed |
| CN-113209050-A | Long-acting in vivo skin-embedded or implanted sustained-release preparation based on biocompatible polymer | 浙江恒冀制药有限责任公司 | 2021-08-06 | — | — | CN | claimed |
| US-11033572-B2 | Molecular adjuvants for enhanced cytosolic delivery of active agents | UNIVERSITEIT GENT (BE) | 2021-06-15 | — | — | US | claimed |
| EP-3233105-B1 | NOVEL COMBINATION AND USE | HELPERBY THERAPEUTICS LTD (GB) | 2020-09-30 | — | — | EP | claimed |
| US-10780177-B2 | Sulfoalkyl ether cyclodextrin compositions | CYDEX PHARMACEUTICALS, INC. (US) | 2020-09-22 | — | — | US | claimed |
| US-20190328768-A1 | MOLECULAR ADJUVANTS FOR ENHANCED CYTOSOLIC DELIVERY OF ACTIVE AGENTS | UNIVERSITEIT GENT (BE) | 2019-10-31 | — | — | US | claimed |
| US-20190321441-A1 | NOVEL COMBINATION AND USE | HELPERBY THERAPEUTICS LIMITED (GB) | 2019-10-24 | — | — | US | claimed |
| US-10350093-B2 | Degradable implantable medical devices | ELIXIR MEDICAL CORPORATION (US) | 2019-07-16 | — | — | US | claimed |
| CN-107530397-A | Novel compositions and purposes | 赫尔普百治疗有限公司 | 2018-01-02 | — | — | CN | claimed |
| US-5955459-A | Fatty acid-antipsychotic compositions and uses thereof | NEUROMEDICA, INC. (US) | 1999-09-21 | — | — | US | claimed |
| EP-0935523-A1 | EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES | GENERAL MILLS, INC. (US) | 1999-08-18 | — | — | EP | claimed |
| WO-1999026661-A1 | A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA | PROTARGA INC. (US) | 1999-06-03 | — | — | WO | claimed |
| WO-1998018610-A1 | EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES | LENGERICH BERNHARD H VAN (US) | 1998-05-07 | — | — | WO | claimed |
| EP-0741570-A1 | METHOD FOR PREVENTING OR REDUCING PHOTOSENSITIVITY AND/OR PHOTOTOXICITY REACTIONS TO MEDICATIONS | G.D. SEARLE & CO. (US) | 1996-11-13 | — | — | EP | claimed |
| WO-1995020387-A1 | METHOD FOR PREVENTING OR REDUCING PHOTOSENSITIVITY AND/OR PHOTOTOXICITY REACTIONS TO MEDICATIONS | G.D. SEARLE & CO. (US) | 1995-08-03 | — | — | WO | claimed |
| EP-0580776-A1 | USE OF SIGMA RECEPTOR ANTAGONISTS TO ENHANCE THE EFFECTS OF ANTIPSYCHOTIC DRUGS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-02-02 | — | — | EP | claimed |
| WO-1992018127-A1 | USE OF SIGMA RECEPTOR ANTAGONISTS TO ENHANCE THE EFFECTS OF ANTIPSYCHOTIC DRUGS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-10-29 | — | — | WO | claimed |
| EP-0180364-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING PHENOTHIAZINES | RECKITT AND COLMAN PRODUCTS LIMITED (GB) | 1990-03-07 | — | — | EP | claimed |
| EP-0180364-A2 | Pharmaceutical compositions containing phenothiazines | RECKITT AND COLMAN PRODUCTS LIMITED (GB) | 1986-05-07 | — | — | EP | claimed |